

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/506592		
		Filing Date	September 3, 2004		
		First Named Inventor	Andrew David Morley		
		Art Unit	NIA-1626		
		Examiner Name	Not Yet Assigned NOLAN		
Sheet	2	of	3	Attorney Docket Number	ASZD-P01-659

IDC-For Ref -23

JMN	BZ	EP-1145717	05-12-2004	Pfizer Products Inc.		
JMN	BA1	EP-1149580	02-21-2001	Pfizer Products Inc.		
JMN	BB1	EP-1177791	07-27-2001	Pfizer Products Inc.		
JMN	BC1	ES-2081747	03-01-1996	Esteve Labor DR		
JMN	BD1	DE-4445968	06-27-1996	Bayer AG		
JMN	BE1	WO-93/25574	12-23-1993	Pfizer Inc.		
JMN	BF1	WO-95/24391	08-14-1995	Novo Nordisk		
JMN	BG1	WO-96/39384	12-12-1996	Pfizer, Inc.		
JMN	BH1	WO-96/39385	12-12-1996	Pfizer Inc.		
JMN	BI1	WO-97/09040	03-13-1997	Novo Nordisk		
JMN	BJ1	WO-97/31901	09-04-1997	Mikael Bols		
JMN	BK1	WO-97/45425	12-04-1997	Fujisawa Pharmaceutical Co., Ltd.		
JMN	BL1	WO-98/27108	06-25-1998	Fuji-Sawa Pharmaceutical Co., Ltd.		
JMN	BM1	WO-98/40353	09-17-1998	Novo Nordisk		
JMN	BN1	WO-98/50359	11-12-1998	Novo Nordisk		
JMN	BO1	WO-99/26659	06-03-1999	Pfizer Products Inc.		
JMN	BP1	WO-99/36393	07-22-1999	Tanabe Seiyaku Co., Ltd.		
JMN	BQ1	JP 2001 089368	04/2001			
JMN	BR1	DD 200740	06-08-1983	Gewald		
JMN	BS1	EP 697403	02-21-1996	Sanofi		
JMN	BT1	JP 2001 206856	07-31-2001	Pfizer Prod. Inc.		
JMN	BU1	JP 021247565	05-14-1990	Hanawa Netsuden Kinzoku KK		
JMN	BV1	JP 04179949	06-26-1992	Toray Ind. Inc.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * Applicant's unique citation designation number (optional). * See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. * Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. * Applicant is to place a check mark here if English language translation is attached.

IDC-Other Ref -5

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	Birch, A., et al., "Novel Thienopyrrole Glycogen Phosphorylase Inhibitors: In Vitro SAR and Crystallographic Studies," Poster, AstraZeneca UK, CVGI Research, Mereside, Atterley Park, Macclesfield, Cheshire.	
JMN	CB	Crochet, R.A., et al., "Synthesis of Substituted Thieno[2,3-b] pyrroles," Vol. 11, 143-150 (April 1974).	
	CC	Freeman, S., et al., "Effect of Glucose on Rat and Human Liver Glycogen Phosphorylase Activity and Potency of a Glycogen Phosphorylase Inhibitor." Diabetes, 53, Supp., 1470-P, A340.	
JMN	CD	Hartman, G.D., et al., "The Synthesis of 5-Alkylaminomethylthieno[2,3-b]Pyrrole-5-Sulfonamides." Heterocycles, 29(10):1943-1949 (1989).	
JMN	CE	Hoover, D.J., et al., "Indole-2-carboxamide Inhibitors of Human Liver Glycogen Phosphorylase," J. Med. Chem., 41:2934-2938 (1998).	
JMN	CF	Hudson, S., et al., "The effect of a glycogen phosphorylase inhibitor upon muscle fatigue in anaesthetised rats," J. Physiol., 539:52-53 (2002).	
JMN	CG	Jakobsen, P., et al., "Iminosugars: Potential Inhibitors of Liver Glycogen Phosphorylase," 200	
Examiner Signature		Date Considered	3-24-2006

Cont. nxt. pg.